Diversity in mRNA therapies has mitigated advancements in the processes for mRNA manufacturing. In vitro transcribed (IVT) mRNA and capping reactions are not universal and must be finely tuned to each molecule based on composition, structure and size. Using literature and experimental design, adapting each method to fit the molecule is necessary for hastening the optimization of development.
Using a multi-modal approach, the featured speaker will investigate the factors that are known to affect the various aspects of mRNA manufacturing and production from yields to purity and integrity. With this in place, the conditions can be defined knowing the target and core assumptions can be developed based on experimentation to develop a framework from which the process can be further built upon. This enables working from a basis beyond a universal design to achieve the final product in a purer more efficient progression.
Register for this webinar to gain insights into a tailored production approach to mRNA manufacturing that optimizes the development process.
Scott Alderucci, Director of mRNA Process Development & GMP Operations, Curia Global, Inc.
Scott Alderucci is the Director of Process Development overseeing the Process Development and GMP divisions of mRNA at Curia. He holds a scientific master’s degree and has 25 years of experience working in the field of biologics focused on DNA, mRNA and antibody platforms. He has worked within such institutions as Millennium Pharmaceuticals, Cellular Genomics, the State of Massachusetts and Shire Pharmaceuticals prior to joining Curia. His current role is focused on providing research and development through GMP level production of a wide range of mRNA products to meet various program goals.
Who Should Attend?
Students/Researchers interested in developing better methods of in vitro transcribed (IVT) mRNA manufacturing
What You Will Learn
Attendees will learn about key steps in a tailored mRNA manufacturing process regarding:
- Subject examination
- Identifying vital methodologies
- Refining and focusing target components
- Proper in-process analytics
Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com.